2026 VB100: Top 50 Most Influential Innovators in China's Healthcare Industry Files Prospectus

As policy dividends continue to be unleashed, technological iterations accelerate, and capital floods in, we have grown accustomed to depicting the rise of an industry through macro-level indicators such as market size, financing rounds, and the number of enterprises. Yet behind these figures, it is the day-to-day, painstaking exploration in laboratories that truly determines the trajectory of technology; it is the incisive, essence-targeting questions raised repeatedly during due diligence meetings that genuinely influence the flow of capital; and it is the unwavering persistence of companies across economic cycles that truly drives product commercialization.

The underlying logic of industrial transformation has always been written by people. People are the most dynamic core variable in industrial innovation.

Innovation in today’s healthcare industry has entered a new phase driven by multi-stakeholder collaboration. Scientists’ breakthroughs in frontier technologies, entrepreneurs’ translation of innovative achievements into practical applications, and investors’ resource linkage and empowerment each exert critical influence within the industry, collectively forming an interlinked innovation chain. Only by breaking down role barriers and recognizing the value of synergy can we truly understand what drives an industry forward. This is precisely“Top 50 Innovators in China’s Healthcare Industry”The original intention behind its establishment.

VCBeat’s 2026 Future Healthcare & Pharma Top 100 Conference will unveil the “Top 50 Influential Innovators in China’s Healthcare Industry,” aiming to transcend single-role perspectives by identifying and honoring key figures who exert significant influence across the entire industrial innovation chain. Encompassing a diverse range of innovators—including entrepreneurs, investors, and scientists—the selection criteria evaluate not only individual innovative practices and industry reach in technology, business, and capital domains, but also emphasize the ecological impact of cross-role collaboration on driving industrial innovation and upgrading.

Differentiated evaluation weights have been established for the core value characteristics of different roles:Industry ScientistAs a source of technological breakthroughs and a driver of their translation into practice, the evaluation focuses on “technological innovation breakthrough capability” and “industrial translation capability of outcomes,” supplemented by assessments of industry value impact such as academic honors and paper influence.Industrial EntrepreneurAs the implementer of commercialization and the definer of business models, it focuses on evaluating “industry innovation leadership” and “commercial conversion capability of outcomes,” supplemented by assessments of value influence such as annual industry honors and participation in industry summits;Industrial InvestorAs an allocator of innovation resources and a connector within the ecosystem, primary emphasis is placed on “judgment in innovation investment” and “post-investment value empowerment,” supplemented by industry value assessments such as the annual impact of investment cases.

Based on the aforementioned classification and weighting system, VCBeat conducted comprehensive assessments, scientific scoring, and holistic evaluations of nearly 200 candidates, ultimately curating this list.

VCBeat believes that,To Understand the Future of an Industry, First Understand the People Driving It。“2026 China Healthcare Industry – Top 50 Innovators”Already in2026 Future Healthcare 100 Awards CeremonyAnnounced on-site, the strategic partner for this awards ceremony isHSBC Sci-Tech Innovation Finance。